Omeros (OMER) Net Equity Issued and Repurchased (2012 - 2025)

Omeros (OMER) reported Net Equity Issued and Repurchased of -$1.3 million for Q4 2025, down 114.57% sequentially from $9.0 million in Q3 2025.

Omeros (OMER) Net Equity Issued and Repurchased (2012 - 2025) Analysis & Trends

Omeros (OMER) has 9 years of Net Equity Issued and Repurchased data on file, last reported at -$1.3 million in Q4 2025.

For the quarter ending Q4 2025, Net Equity Issued and Repurchased changed N/A year-over-year to -$1.3 million; the trailing twelve-month figure through Dec 2025 stood at $7.7 million (down 85.81% YoY), and the FY2025 full-year result was $19.0 million, changed N/A from the prior year.
Net Equity Issued and Repurchased declined to -$1.3 million in Q4 2025, from $9.0 million in the prior quarter.
In the past five years, Net Equity Issued and Repurchased ranged from a high of $9.0 million in Q3 2025 to a low of -$1.3 million in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Equity Issued and Repurchased (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	163.10 Mn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	141.90 Mn
10	Omeros	739.31 Mn	739.31 Mn	9.31 Mn	-

Download Data